Orphan Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)

Global Orphan Drugs Market is expected to garner $172 billion from $110 billion and register a CAGR of 7.0% during the forecast period, 2018-2024. An orphan drug is a pharmaceutical agent specifically designed to treat rare (orphaned) diseases. These diseases differ from usual diseases as their prevalence rate is very low and hence address to a very small patient population.

Orphan Drugs Market Share:

In the disease type segment, oncologic diseases occupied dominant share in 2018. In addition, it is expected to maintain the trend during the forecast period. This is due to the array of different forms of rare cancers, such as leukaemia, myeloma, angiosarcoma, and others prevalent in the patient population.

Orphan Drugs Market Size:

The orphan drugs market was dominated by America, which accounted for more than 59% of the total market share in 2018. Factors like the increasing government incentives and high product demand are expected to promote market growth in the US region, which is considered to be the highest revenue-generating region in America.

Orphan Drugs Market Growth:

The demand for the orphan drugs has increased significantly owing to surge in the prevalence of rare diseases. In addition, the rise in awareness among the populace regarding rare diseases, increase in R&D investment, and drug development is driving the market growth.

Orphan Drugs Market Industry Analysis:

The global orphan drugs market is segmented by type, top-selling drugs, therapeutic area, disease type, indication. The type segment is further divided into biological and non-biological orphan drugs; top-selling drugs into the top 20 selling drugs, globally; and therapeutic area into oncology, haematology, neurology, cardiovascular, ophthalmology and others. Based on disease type, the industry is divided into oncologic diseases, metabolic diseases, hematologic & immunologic diseases, infectious diseases, neurologic diseases, and other rare diseases.

Orphan Drugs Market Outlook:

Therefore, as compared to non-orphan drugs, these drugs do not guarantee feasible returns on investment. However, various government authorities encourage to develop and market such drugs. The cost associated with the development of these drugs is higher when compared with non-orphan drugs. The different indications for which orphan drugs are used include lymphoma, leukaemia, cystic fibrosis, and others.

Orphan Drugs Market Trends:

GlaxoSmithKline announced that the US Food and Drug Administration (FDA) has approved Nucala as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome. GSK submitted a supplemental Biologics License Application for mepolizumab, an interleukin-5 (IL-5) antagonist.

Orphan Drugs Market Research report includes:

• An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
• To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOT analysis, and Y-o-Y analysis.
• Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
• Identifying DROC in the current market and their impact in altering the market dynamics.
• Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
• Expertise investment opportunities by an analyst to the individual and organization to have a better foothold in the market.
• Identify the latest developments, market shares and strategies that are employed by the major market players, such as
• GlaxoSmithKline PLC
• Roche
• Sanofi
• NovartisAegerion Pharmaceuticals, Inc